You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Where Are We Now in the Use of Interleukin-17 Inhibitors for Psoriatic Disease?

  • Authors: Melinda Gooderham, MD, MSc, FRCP; Laura Coates, MD, PhD; Mark G. Lebwohl, MD
  • CME / ABIM MOC Released: 1/3/2023
  • Valid for credit through: 1/3/2024
Start Activity

  • Credits Available

    Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.75 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for dermatologists, rheumatologists, and primary care physicians.

The goal of this activity is for learners to be better able to relate the most recent data on psoriasis and PsA from recent conferences to their clinical practice.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical data on emerging interleukin-17 (IL-17) inhibitors in psoriatic disease
    • Clinical data relating to disease biology
  • Demonstrate greater confidence in their ability to
    • Optimize care for patients with psoriatic disease


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Moderator

  • Melinda Gooderham, MD, MSc, FRCP

    Assistant Professor
    Queens University
    Medical Director
    SKiN Centre for Dermatology
    Peterborough, Ontario, Canada

    Disclosures

    Melinda Gooderham, MD, MSc, FRCP, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie, Inc.; Akros Pharma Inc.; Amgen, Inc.; AnaptysBio, Inc.; Arcutis Biotherapeutics, Inc.; Aristea Therapeutics; Asana BioSciences, LLC; Aslan Pharmaceuticals; Bausch Health Companies Inc.; Boehringer Ingelheim International GmbH; Celgene Corporation; Eli Lilly and Company; Galderma Laboratories, L.P.; Janssen, Inc.; Kyowa Kirin Pharmaceutical Development, Inc.; LEO Pharma, Inc.; Novartis Pharmaceuticals; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme; Sun Pharmaceuticals Industries, Ltd. UCB Pharma, Inc.
    Speaker or member of speakers bureau for: AbbVie, Inc.; Amgen; Arcutis Biotherapeutics, Inc.; Aslan Pharmaceuticals; Bausch Health Companies Inc.; Boehringer Ingelheim International GmbH; Celgene Corporation; Eli Lilly and Company; Galderma SA; Janssen, Inc.; LEO Pharma, Inc.; Novartis Pharmaceuticals; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme; Sun Pharmaceutical Industries, Ltd.; UCB Pharma, Inc. 
    Research funding from: AbbVie, Inc.; Akros Pharma Inc.; Amgen, Inc.; AnaptysBio, Inc.; Arcutis Biotherapeutics, Inc.; Aristea Therapeutics; Aslan Pharmaceuticals; Bausch Health Companies Inc.; Boehringer Ingelheim International GmbH; Bristol Myers Squibb Company; Celgene Corporation; Coherus Biosciences; Dermira Inc.; Eli Lilly and Company; Galderma SA; GlaxoSmithKline; Incyte Corporation; Janssen, Inc.; Kyowa Kirin Pharmaceutical Development, Inc.; LEO Pharma, Inc.; MedImmune Inc.; Merck and Co.; MoonLake Immunotherapeutics; Nimbus Therapeutics; Novartis Pharmaceuticals; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme; Sun Pharmaceutical Industries, Ltd.; UCB Pharma, Inc.

Faculty

  • Laura Coates, MD, PhD

    Associate Professor​
    University of Oxford​
    Oxford, United Kingdom​

    Disclosures

    Laura Coates, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie, Inc.; Amgen, Inc.; Bristol Myers Squibb Company; Celgene Corporation; Eli Lilly and Company; Galapagos; Gilead Sciences, Inc.; Janssen; MoonLake Immunotherapeutics; Novartis; Pfizer, Inc.; UCB Pharma, Inc.
    Speaker or member of speakers bureau for: AbbVie, Inc.; Amgen, Inc.; Biogen; Celgene Corporation; Eli Lilly and Company; Galapagos; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen; Medac Pharma, Inc.; Novartis; Pfizer, Inc.; UCB Pharma, Inc.
    Research funding from: AbbVie, Inc.; Amgen, Inc.; Celgene Corporation; Eli Lilly and Company; Janssen; Novartis; Pfizer, Inc.; UCB Pharma, Inc.

  • Mark G. Lebwohl, MD

    Dean for Clinical Therapeutics
    Chairman Emeritus
    Department of Dermatology
    Icahn School of Medicine at Mount Sinai
    New York, New York, United States

    Disclosures

    Mark G. Lebwohl, MD, has the following relevant financial relationships:
    Consultant or advisor for: AnaptysBio, Inc.; Arcutis Biotherapeutics, Inc.; Arena Pharmaceuticals, Inc.; Aristea Therapeutics; Avotres Therapeutics; BioMX; Boehringer Ingelheim Pharmaceuticals, Inc.; Brickell Biotech; Castle Biosciences; Corevitas; Dermavant Sciences, Inc.; Evommune, Inc.; Forte Biosciences; Hexima Ltd.; Meiji Seika Kaisha, Ltd.; Mindera; Pfizer, Inc.; Seanergy; Verrica Pharmaceuticals; Vial
    Research funding from: AbbVie, Inc.; Amgen, Inc.; Arcutis Biotherapeutics, Inc.; Avotres Therapeutics; Boehringer Ingelheim Pharmaceuticals, Inc.; Cara Therapeutics; Dermavant Sciences, Inc.; Incyte Corporation; Inozyme; Janssen Research & Development LLC; Lilly USA, LLC; Novartis; Ortho Dermatologics; Regeneron; UCB Pharma, Inc.

Editors

  • Marinella Calle, PhD, CMPP

    Senior Medical Education Director, WebMD Global, LLC

    Disclosures

    Marinella Calle, PhD, CMPP, has no relevant financial relationships.

  • Diana Lucifero, PhD

    Scientific Content Manager, WebMD Global, LLC

    Disclosures

    Diana Lucifero, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Where Are We Now in the Use of Interleukin-17 Inhibitors for Psoriatic Disease?

Authors: Melinda Gooderham, MD, MSc, FRCP; Laura Coates, MD, PhD; Mark G. Lebwohl, MDFaculty and Disclosures

CME / ABIM MOC Released: 1/3/2023

Valid for credit through: 1/3/2024

processing....

Commentaire d'expert en français

Ce commentaire fait partie d’une activité de formation plus vaste. Après la participation, prière de retourner à  Where Are We Now in the Use of Interleukin-17 Inhibitors for Psoriatic Disease?  pour accéder à l’ensemble du contenu de formation relié. 

 
« Return to: Where Are We Now in the Use of Interleukin-17 Inhibitors for Psoriatic Disease?
  • Print